23 completed, 5 unknown, 4 terminated, 1 enrolling by invitation. 34 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 34 | Completed 23, Unknown 5, Terminated 4, Enrolling by invitation 1, Recruiting 1 |
Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Osilodrostat and Cabergoline in Cushing's Disease osilodrostat, osilodrostat and cabergoline - Cushing Disease Due to Increased ACTH Secretion | Phase 4 | Enrolling by invitation | University of Basrah | 50 | 2026-05-11 | 2026-05-22 |
| Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment Cabergoline (Dopamine Agonist) - Prolactinoma | Phase 4 | Recruiting | University Hospital, Basel, Switzerland | 60 | 2025-09-16 | 2025-09-23 |
| Pasireotide LAR and Pegvisomant Study in Acromegaly Pasireotide LAR 60 mg, Pegvisomant - Acromegaly | Phase 4 | Unknown | Erasmus Medical Center | 60 | 2015-08-01 | 2016-08-03 |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Pasireotide s.c., Sitagliptin, Liraglutide - Cushing's Disease, Acromegaly | Phase 4 | Completed | Novartis Pharmaceuticals | 249 | 2014-05-23 | 2019-05-29 |
| Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Sandostatin (Octreotide Acetate) - Acromegaly | Phase 4 | Unknown | Asan Medical Center | 1 | 2014-03-01 | 2015-04-28 |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Pasireotide, Cabergoline, Pasireotide LAR - Cushing's Disease, Acromegaly | Phase 4 | Completed | RECORDATI GROUP | 337 | 2013-06-10 | 2024-10-01 |
| A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. lanreotide - Acromegaly | Phase 4 | Terminated | Saint John's Cancer Institute | 4 | 2013-05-01 | 2021-09-30 |
| Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Pasireotide 0.6 MG/ML - Cushing Disease | Phase 4 | Completed | University of Palermo | 24 | 2013-05-01 | 2017-10-27 |
| A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Aripiprazole, risperidone or paliperidone - Sexual Dysfunction, Hyperprolactinemia | Phase 4 | Unknown | Si Tianmei | 120 | 2013-02-01 | 2013-03-14 |
| Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Sandostatin® LAR - Acromegaly | Phase 4 | Completed | University of Aarhus | 84 | 2012-06-01 | 2017-01-26 |
| Aripiprazole and Prolactin Study Aripiprazole - Hyperprolactinemia | Phase 4 | Completed | University of Oxford | 15 | 2010-04-01 | 2015-05-28 |
| Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation Amantadine Hydrochloride, USP, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 4 | Terminated | David C. Henderson, MD | 6 | 2009-10-01 | 2013-06-10 |
| The Luveris In Vitro Fertilization Trial Luveris fixed dose, Luveris increasing dose - Infertility, Hypothalamic Amenorrhea | Phase 4 | Terminated | University Reproductive Associates | 14 | 2009-04-01 | 2018-08-07 |
| Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Lanreotide Autogel 120 mg - Acromegaly | Phase 4 | Completed | Ipsen | 124 | 2008-10-01 | 2019-01-29 |
| Endometriosis Patients Undergoing Quinagolide Treatment ENDOMETRIAL BIOPSY - Hyperprolactinemia, Endometriosis | Phase 4 | Completed | Instituto Valenciano de Infertilidad, IVI VALENCIA | 5 | 2008-02-01 | 2009-01-12 |
| Acute Application of Pegvisomant and Octreotide in Acromegaly pegvisomant, combination with somatostatin analogue octreotide, combination with dopamine agonist cabergoline - Acromegaly | Phase 4 | Completed | Ludwig-Maximilians - University of Munich | 10 | 2008-01-01 | 2008-04-01 |
| Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Abilify (aripiprazole) - Hyperprolactinemia, Weight Gain | Phase 4 | Unknown | Genovate Biotechnology Co., Ltd., | 2007-10-01 | 2007-10-10 | |
| Ultrasound Guided Octreotide LAR Injection in Acromegaly Octreotide LAR 30 MG Injection - Acromegaly | Phase 4 | Completed | Cedars-Sinai Medical Center | 15 | 2007-07-01 | 2018-09-11 |
| Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Pegvisomant - Quality of Life, Acromegaly | Phase 4 | Completed | Erasmus Medical Center | 20 | 2006-10-01 | 2008-03-25 |
| Effects of Sandostatin LAR® in Acromegaly Sandostatin LAR - Acromegaly | Phase 4 | Completed | Columbia University | 21 | 2006-10-01 | 2024-07-24 |
Showing 20 of 34. Sign in to see all of them.
Acromegaly (25) · Hyperprolactinemia (7) · Pituitary ACTH Hypersecretion (4) · Pituitary Neoplasms (4) · Neoplasms (2) · Schizophrenia (2) · Adrenal Insufficiency (1) · Brain Neoplasms (1) · Cardiomegaly (1) · Dumping Syndrome (1) · Dyslipidemias (1) · Endometriosis (1) · Gigantism (1) · Heart Failure (1) · Hyperandrogenism (1)
Brain Diseases (34) · Central Nervous System Diseases (34) · Endocrine System Diseases (34) · Hypothalamic Diseases (34) · Nervous System Diseases (34) · Pituitary Diseases (34) · Bone Diseases (25) · Bone Diseases, Endocrine (25) · Musculoskeletal Diseases (25) · Endocrine Gland Neoplasms (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Central Nervous System Neoplasms (4) · Genital Diseases (4)
pegvisomant (8) · Octreotide (6) · Cabergoline (5) · lanreotide (4) · pasireotide (4) · Aripiprazole (3) · Amantadine (1) · Demography (1) · Dopamine Agonists (1) · Glucose Tolerance Test (1) · Health Records, Personal (1) · Injections (1) · Insulin (1) · Liraglutide (1) · Luteinizing Hormone, beta Subunit (1)
Novartis Pharmaceuticals (5) · Ipsen (3) · Pfizer (3) · Erasmus Medical Center (2) · Federico II University (2) · Asan Medical Center (1) · Cedars-Sinai Medical Center (1) · Columbia University (1) · David C. Henderson, MD (1) · Genovate Biotechnology Co., Ltd., (1) · Instituto Valenciano de Infertilidad, IVI VALENCIA (1) · Ludwig-Maximilians - University of Munich (1) · Odense University Hospital (1) · RECORDATI GROUP (1) · Saint John's Cancer Institute (1)
United States (9) · Germany (7) · Italy (6) · Brazil (5) · France (5) · Spain (5) · Canada (4) · Denmark (4) · Netherlands (4) · Norway (4) · Poland (4) · United Kingdom (4) · Australia (3) · Greece (3) · Mexico (3)
Abbas A Mansour (1) · Annamaria AL Colao, Prof. (1) · Annamaria Colao, MD, PhD (1) · Bruno Allolio, MD (1) · Chen Chih-Ken, PhD (1) · Cihan Atila, Dr. (1) · Daniel F Kelly, MD (1) · David C. Henderson, M.D. (1) · Guy M Goodwin, PhD (1) · Haider A Alidrisi (1) · Ibrahim H Hussein, MD (1)
PMID 15613435, PMID 15827109, PMID 10469005, PMID 10690849, PMID 10999798, PMID 11397887, PMID 11788630, PMID 12843148, PMID 14764779, PMID 15070920, PMID 15080776, PMID 15080778, PMID 15099442, PMID 15362960, PMID 15886238, PMID 15886256, PMID 16373932, PMID 16449332, PMID 16487447, PMID 16537687, PMID 16918950, PMID 17259801, PMID 17555511, PMID 17892497, PMID 17984237, PMID 18492760, PMID 19094074, PMID 20003832, PMID 20732372, PMID 21055747, PMID 21521254, PMID 24092547, PMID 24866574, PMID 27405306, PMID 29155991, PMID 34275099, PMID 3899825, PMID 5427331, PMID 8050136, PMID 8327647, PMID 8514973, PMID 9709939, PMID 9768640, PMID 9768641, PMID 9808008
2005 (1), 2009 (1), 2014 (1), 2025 (1)